Safety biomarker applications in drug development

Shelli Schomaker1, Shashi Ramaiah1, Nasir Khan1

  • 1Drug Safety R&D, Pfizer, Inc, CT, USA.

Insights

Safety biomarkers are crucial for early drug development, aiding in monitoring organ toxicities like kidney and liver. Despite progress, gaps remain for other organs, necessitating further research and qualification for broader clinical trial application.

Area of Science:

  • Pharmacology
  • Toxicology
  • Biomarker Discovery

Background:

  • Translational safety biomarkers are essential for assessing drug safety in early clinical trials, particularly when therapeutic exposure margins are narrow.
  • While progress has been made in identifying biomarkers for kidney and liver toxicities, significant gaps persist for other organs such as the testis and pancreas.
  • Precompetitive consortia, including the Predictive Safety Testing Consortia (PSTC) and Innovative Medicines Initiative (IMI), are actively working to qualify biomarkers for broader use.

Purpose of the Study:

  • To discuss the complexities involved in the discovery, validation, and international regulatory qualification of novel safety biomarkers for clinical trial applications.
  • To highlight specific examples and insights from Pfizer Research and Development regarding safety biomarker implementation.
  • To emphasize the role of qualified safety biomarkers in accelerating drug development and facilitating therapeutic progression.

Main Methods:

  • Review of current landscape and challenges in safety biomarker development.
  • Discussion of precompetitive consortia efforts (PSTC, IMI) in biomarker qualification.
  • Presentation of case examples from pharmaceutical industry research (Pfizer R&D).

Main Results:

  • Progress in identifying and implementing safety biomarkers for certain organ toxicities (kidney, liver).
  • Identification of existing biomarker gaps for other critical organs (testis, pancreas).
  • Emphasis on the collaborative efforts of industry, academia, and regulatory bodies in biomarker qualification.

Conclusions:

  • Qualified safety biomarkers are increasingly vital for early clinical trials, enhancing decision-making processes.
  • The acceptance and qualification of safety biomarkers by regulatory agencies will accelerate the progression of promising therapeutics.
  • Addressing biomarker gaps and fostering collaborative efforts are key to advancing drug safety assessment.

Related Concept Videos

Survey Safety01:28

Survey Safety

Surveying near highways, rough terrain, or power lines involves significant risks. Working along highways is particularly dangerous and requires the use of warning signs and flagmen. It is safest to avoid working directly on roads and use offsets whenever possible. When highway work is unavoidable, it must follow all safety guidelines. Surveyors should wear bright clothing, such as orange reflective vests, to ensure visibility to motorists, coworkers, and hunters. In construction zones, wearing...
381
Household Wiring And Electrical Safety01:13

Household Wiring And Electrical Safety

Companies that supply power to most modern households use three conductors, typically called a three-wire line. While one is neutral, the other two are both at 120 V but with opposite polarity, giving a voltage of 240 V between them. With a three-wire line, high-power appliances that require 240 V, such as electric stoves and clothes dryers, are linked between the two hot lines. 120 V appliances can be connected between the neutral and either of the hot lines. The neutral side, which is always...
1.6K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
324
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
840
Sustainable Development01:43

Sustainable Development

As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
14.8K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
425